Type I IFNs which mainly include IFNα and IFNβ are important regulators of innate and adaptive immune responses, such as activation of DCs and promoting survival of CTLs.[31] Our previous studies have demonstrated that type I IFN signaling is generally deactivated during tumor progression,[23, 32] suggesting that re‐activating type I IFN signaling would be critical for anti‐tumor immunity. Here, IFNB1 is linked to neoplasm.